Cost-Utility Analysis Of Apixaban In The Acute Treatment And Prevention Of Venous Thromboembolism In France.

SoC and SoC alone gained 0.3155 QALYs and 0.2752 QALYs, respectively. Hence, ranolazine plus SoC resulted in an ICER of € 4,620 per QALY gained, well below the threshold of € 34,000 per QALY gained, that is twice the annual per capita income. The PSA showed that the likelihood of ranolazine plus SoC being cost-effective at the threshold of € 34,000 per QALY gained was 100%. ConClusions: The results suggest that ranolazine as add–on treatment may be a cost-effective alternative for the symptomatic treatment of patients with chronic stable angina in Greece.